Literature DB >> 25210085

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25210085     DOI： 10.1093/annonc/mdu255

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  144 in total

1.  Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets.

Authors:  Ellen Heitzer; Sandra Sunitsch; Magdalena M Gilg; Birgit Lohberger; Beate Rinner; Karl Kashofer; Nicole Stündl; Peter Ulz; Joanna Szkandera; Andreas Leithner; Bernadette Liegl-Atzwanger
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Laparoscopic resection for gastrointestinal stromal tumors in esophagogastric junction (EGJ): how to protect the EGJ.

Authors:  Wenjun Xiong; Jiaming Zhu; Yansheng Zheng; Lijie Luo; Yaobin He; Hongming Li; Dechang Diao; Liaonan Zou; Jin Wan; Wei Wang
Journal:  Surg Endosc       Date:  2017-08-04       Impact factor: 4.584

3.  Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.

Authors:  Jian-Xian Lin; Qing-Feng Chen; Chao-Hui Zheng; Ping Li; Jian-Wei Xie; Jia-Bin Wang; Jun Lu; Qi-Yue Chen; Long-Long Cao; Mi Lin; Ru-Hong Tu; Chang-Ming Huang
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-12       Impact factor: 4.553

4.  Microscopic positive tumor margin does not increase the rate of recurrence in endoscopic resected gastric mesenchymal tumors compared to negative tumor margin.

Authors:  Yan Zhu; Mei-Dong Xu; Chen Xu; Xiao-Cen Zhang; Shi-Yao Chen; Yun-Shi Zhong; Yi-Qun Zhang; Wei-Feng Chen; Tian-Yin Chen; Jia-Xin Xu; Li-Qing Yao; Quan-Lin Li; Ping-Hong Zhou
Journal:  Surg Endosc       Date:  2019-05-28       Impact factor: 4.584

5.  Outcomes After Surgical Resection Differ by Primary Tumor Location for Metastatic Gastrointestinal Stromal Tumors (GISTs): a Propensity Score Matching Population Study.

Authors:  Apostolos Gaitanidis; Michail Alevizakos; Alexandra Tsaroucha; Michail Pitiakoudis
Journal:  J Gastrointest Cancer       Date:  2019-12

6.  Prognostic factors after imatinib secondary resistance: survival analysis in patients with unresectable and metastatic gastrointestinal stromal tumors.

Authors:  Tatsuo Kanda; Takashi Ishikawa; Shin-Ichi Kosugi; Kyo Ueki; Tetsuya Naito; Toshifumi Wakai; Seiichi Hirota
Journal:  Int J Clin Oncol       Date:  2015-09-19       Impact factor: 3.402

7.  Partial response to imatinib treatment in a patient with unresectable gastrointestinal stromal tumor: A case report and mini literature review.

Authors:  Xiaolong Wu; Libo Feng; Qing Liu; Dong Xia; Liang Xu
Journal:  Exp Ther Med       Date:  2016-08-23       Impact factor: 2.447

8.  Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors.

Authors:  Virginie Nerich; Camille Fleck; Loïc Chaigneau; Nicolas Isambert; Christophe Borg; Elsa Kalbacher; Marine Jary; Pauline Simon; Xavier Pivot; Jean-Yves Blay; Samuel Limat
Journal:  Clin Drug Investig       Date:  2017-01       Impact factor: 2.859

9.  Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.

Authors:  Benjamin L Lampson; Mizuki Nishino; Suzanne E Dahlberg; Danie Paul; Abigail A Santos; Pasi A Jänne; Geoffrey R Oxnard
Journal:  Cancer       Date:  2016-08-15       Impact factor: 6.860

10.  Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis.

Authors:  J Martin-Broto; V Martinez-Marín; C Serrano; N Hindi; J A López-Guerrero; R Ramos-Asensio; A Vallejo-Benítez; D Marcilla-Plaza; R González-Cámpora
Journal:  Clin Transl Oncol       Date:  2016-12-09       Impact factor: 3.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.